AMS · American Shared Hospital Services
AI read · Good for AMS
The AI's read
AMS posted 19% YoY revenue growth to $8.4m in Q2 and is pivoting from equipment leasing to patient-facing oncology services. Management flagged stronger utilization, new centers, and an 80%+ cash balance increase, which matter for small-cap recovery. The stock only nudged +2.6% after the call and RSI is very low at 7.02, so the market hasn’t fully re-rated the story. There’s a receivable charge in Rhode Island and execution risk on new centers that keep the setup from being bulletproof. Bottom line: we lean bullish. Execution and capital plans are the obvious watchpoints, but revenue, cash flow, and strategic direction give asymmetric upside if they deliver.